The global Oncology Based In-vivo CRO market size is expected to be worth around US$ 11.5 billion by 2030, according to a new report by Vision Research Reports.
The global Oncology Based In-vivo CRO market size was valued at US$ 725.0 million in 2020 and is anticipated to grow at a CAGR of 18.0 % during forecast period 2021 to 2030.
The use of Contract Research Organization (CRO) oncology services helps the manufacturers/sponsors to provide complete attention on the production capacity and at enhancing their in-house processes.
Furthermore, the pressure from the increasing competition due to patent expirations, rapid growth of generics, and introduction of biosimilar equivalents are propelling the pharmaceutical companies to take the aid of such organizations. Hence, it can be predicted that the oncology based in-vivo CRO market may witness lucrative growth over the forecast period.
Another factor propelling growth is the increasing incidence of cancer, and high failure rate of existing treatment options. According to statistics published by the World Health Organization (WHO), approximately 8.2 million deaths are recorded each year from cancer, which accounts for 13.0% deaths worldwide.
The oncology based in-vivo CRO market has been analyzed based on blood cancer, solid tumors, and other indications. Solid tumors dominate the segment as of 2020 with over 40.0% of the market share.
The factors responsible for higher research in the field of solid tumors include the presence of over 800 new molecules that are in pipeline by large pharmaceutical companies, availability of grants from institutes such as the NIH and NCI, and existing gap between demand and supply of treatments for solid cancer.
According to statistics provided by the government bodies across the world, besides infectious diseases’ vaccine development, oncology is one of the most researched indications. According to the Wilmot Cancer Institute, as of 2015, rigorous studies in the preclinical phase for a new class of drugs called tyrosine kinase inhibitors are being conducted.
Solid tumors are cancer occurring within organs, muscles, or bones. These are generally addressed as carcinomas and sarcomas. The increasing incidence of cancer across the globe and growing interest of world agencies such as the WHO in analyzing their prevalence, causative agents, and treatment options are boosting the R&D. For instance, BioInvent, a Swedish CRO is currently performing multiple preclinical oncology research in collaboration with players such as Bayer Healthcare, Daiichi Sankyo, and Servier.
Based on the type of model employed to conduct research, the global market of oncology based in-vivo CRO is segmented into syngeneic, xenograft, and Patient-Derived Xenograft (PDX) models. As of 2020, PDX forms the largest as well as the fastest-growing segment over the forecast period. Before PDX, xenograft models held a substantial market share owing to the benefits of incorporating the targeted tumor cells within the animal models.
The PDX models allow for a higher correlation between the researched outcome and final therapeutic impacts observed within clinical trial participants and are thus becoming the choice of model among researchers. This segment is expected to grow at a CAGR of over 8.0%.
PDX mice models are the most commonly used approaches for validating the results obtained in the in-vivo studies of cancer drug candidates. The preclinical studies for cancer are driven by the personalized approach, which is the current trending therapy. In 2014, GuizhongLui of Crown Bioscience, Inc. published a paper stating the advantages of using a Patient-Derived Xenograft (PDX) model in mice.
According to our analysis, these xenografts reduce both the time taken to conduct studies as well as the attached costs leading to faster and precise decisions for drug development. Furthermore, a combination of these models when applied together with bioinformatics aids in the selection of appropriate human groups, which in turn leads to the non-erroneous selection of candidates for the clinical trials.
Various organizations across the globe are dedicated to studying oncology in animal models. For instance, The University of California, San Francisco’s Helen Diller Family Comprehensive Cancer Center performs preclinical trials in tumor-bearing animals. The organization on a subscription basis shares its knowledge, expertise, and provide training to other institutes.
Regionally, the U.S. market is most dominant, thereby making North America the largest revenue generator for the oncology based in-vivo CRO market. The presence of ample funding in this region impacted the research activities positively. Moreover, major pharmaceutical and life sciences companies that are involved in drug development are present in this region. With well-planned regulatory and funding policies, the market in this region held remunerative shares.
The U.S. has the highest per capita healthcare spending and availability of funding and grants from government organizations. For instance, according to data provided by the NIH, in 2012 about 47.0% of the total funding allotted for research was spent within the preclinical analysis space.
Factors identified to support this growth include the rapidly evolving healthcare infrastructure and inclusion of research activities by the medium as well as small scale players. Furthermore, the augmenting figure of patients within the region coupled with flexible regulatory guidelines are expected to promote the region as a key destination to existing CROs.
the Australian CRO Novotech started a new office in China, its ninth office in Asia. Novotech, as a company, has expanded in many developing nations owing to the request by its U.S and EU clients. Also, in February 2014, the Charles River Laboratories expressed their interest to enter into the Chinese market owing to the large population base and limited player
Crown Bioscience, Charles River Laboratory, ICON Plc., Eurofins Scientific, Taconic Biosciences, Covance, EVOTEC, The Jackson Laboratory, and Wuxi AppTec. Other players operating in this space are MI Bioresearch, Inc., Living Tumor Laboratory, Champion Oncology, Inc., and Xentech.
Patient-Derived Xenograft (PDX)
The Middle East and Africa (MEA)
The Oncology Based In-vivo CRO market research report covers definition, classification, product classification, product application, development trend, product technology, competitive landscape, industrial chain structure, industry overview, national policy and planning analysis of the industry, the latest dynamic analysis, etc., and also includes major. The study includes drivers and restraints of the global market. It covers the impact of these drivers and restraints on the demand during the forecast period. The report also highlights opportunities in the market at the global level.
The report provides size (in terms of volume and value) of Oncology Based In-vivo CRO market for the base year 2020 and the forecast between 2021 and 2030. Market numbers have been estimated based on form and application. Market size and forecast for each application segment have been provided for the global and regional market.
This report focuses on the global Oncology Based In-vivo CRO market status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Oncology Based In-vivo CRO market development in United States, Europe and China.
It is pertinent to consider that in a volatile global economy, we haven’t just conducted Oncology Based In-vivo CRO market forecasts in terms of CAGR, but also studied the market based on key parameters, including Year-on-Year (Y-o-Y) growth, to comprehend the certainty of the market and to find and present the lucrative opportunities in market.
In terms of production side, this report researches the Oncology Based In-vivo CRO capacity, production, value, ex-factory price, growth rate, market share for major manufacturers, regions (or countries) and type.
In terms of consumption side, this report focuses on the consumption of Oncology Based In-vivo CRO by regions (countries) and application.
Buyers of the report will have access to verified market figures, including global market size in terms of revenue and volume. As part of production analysis, the authors of the report have provided reliable estimations and calculations for global revenue and volume by Type segment of the global Oncology Based In-vivo CRO market. These figures have been provided in terms of both revenue and volume for the period 2017 to 2030. Additionally, the report provides accurate figures for production by region in terms of revenue as well as volume for the same period. The report also includes production capacity statistics for the same period.
With regard to production bases and technologies, the research in this report covers the production time, base distribution, technical parameters, research and development trends, technology sources, and sources of raw materials of major Oncology Based In-vivo CRO market companies.
Regarding the analysis of the industry chain, the research of this report covers the raw materials and equipment of Oncology Based In-vivo CRO market upstream, downstream customers, marketing channels, industry development trends and investment strategy recommendations. The more specific analysis also includes the main application areas of market and consumption, major regions and Consumption, major Chinese producers, distributors, raw material suppliers, equipment providers and their contact information, industry chain relationship analysis.
The research in this report also includes product parameters, production process, cost structure, and data information classified by region, technology and application. Finally, the paper model new project SWOT analysis and investment feasibility study of the case model.
Overall, this is an in-depth research report specifically for the Oncology Based In-vivo CRO industry. The research center uses an objective and fair way to conduct an in-depth analysis of the development trend of the industry, providing support and evidence for customer competition analysis, development planning, and investment decision-making. In the course of operation, the project has received support and assistance from technicians and marketing personnel in various links of the industry chain.
The Oncology Based In-vivo CRO market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related to Oncology Based In-vivo CRO market.
Prominent players in the market are predicted to face tough competition from the new entrants. However, some of the key players are targeting to acquire the startup companies in order to maintain their dominance in the global market. For a detailed analysis of key companies, their strengths, weaknesses, threats, and opportunities are measured in the report by using industry-standard tools such as the SWOT analysis. Regional coverage of key companies is covered in the report to measure their dominance. Key manufacturers of Oncology Based In-vivo CRO market are focusing on introducing new products to meet the needs of the patrons. The feasibility of new products is also measured by using industry-standard tools.
Key companies are increasing their investments in research and development activities for the discovery of new products. There has also been a rise in the government funding for the introduction of new Oncology Based In-vivo CRO market. These factors have benefited the growth of the global market for Oncology Based In-vivo CRO. Going forward, key companies are predicted to benefit from the new product launches and the adoption of technological advancements. Technical advancements have benefited many industries and the global industry is not an exception.
New product launches and the expansion of already existing business are predicted to benefit the key players in maintaining their dominance in the global market for Oncology Based In-vivo CRO. The global market is segmented on the basis of region, application, en-users and product type. Based on region, the market is divided into North America, Europe, Asia-Pacific, Latin America and Middle East and Africa (MEA).
In this study, the years considered to estimate the market size of Oncology Based In-vivo CRO are as follows:
Reasons to Purchase this Report:
- Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects
- Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
- Market value USD Million and volume Units Million data for each segment and sub-segment
- Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
- Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players
In-depth interviews and discussions were conducted with several key market participants and opinion leaders to compile the research report.
This research study involved the extensive usage of both primary and secondary data sources. The research process involved the study of various factors affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry, and market risks, opportunities, market barriers and challenges. The following illustrative figure shows the market research methodology applied in this report.
Market Size Estimation
Top-down and bottom-up approaches are used to estimate and validate the global market size for company, regional division, product type and application (end users).
The market estimations in this report are based on the selling price (excluding any discounts provided by the manufacturer, distributor, wholesaler or traders). Market share analysis, assigned to each of the segments and regions are achieved through product utilization rate and average selling price.
Major manufacturers & their revenues, percentage splits, market shares, growth rates and breakdowns of the product markets are determined through secondary sources and verified through the primary sources.
All possible factors that influence the markets included in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data. The market size for top-level markets and sub-segments is normalized, and the effect of inflation, economic downturns, and regulatory & policy changes or others factors are accounted for in the market forecast. This data is combined and added with detailed inputs and analysis from Vision Research Reports and presented in this report.
Market Breakdown and Data Triangulation
After complete market engineering with calculations for market statistics; market size estimations; market forecasting; market breakdown; and data triangulation. Extensive primary research was conducted to gather information and verify and validate the critical numbers arrived at. In the complete market engineering process, both top-down and bottom-up approaches were extensively used, along with several data triangulation methods, to perform market estimation and market forecasting for the overall market segments and sub-segments listed in this report.
Secondary Sources occupies approximately 25% of data sources, such as press releases, annual reports, Non-Profit organizations, industry associations, governmental agencies and customs data, and so on. This research study includes secondary sources; directories; databases such as Bloomberg Business, Wind Info, Hoovers, Factiva (Dow Jones & Company), TRADING ECONOMICS, and avention; Investing News Network; statista; Federal Reserve Economic Data; annual reports; investor presentations; and SEC filings of companies.
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include product manufacturers (and their competitors), opinion leaders, industry experts, research institutions, distributors, dealer and traders, as well as the raw materials suppliers and producers, etc.
The primary sources from the demand side include industry experts such as business leaders, marketing and sales directors, technology and innovation directors, supply chain executive, end users (product buyers), and related key executives from various key companies and organizations operating in the global market.
The study objectives of this report are:
Orthopedic Soft Tissue Repair Market Size, Share, Trends, Growth, Production, Consumption, Revenue, Company Analysis and Forecast 2021-2030Read more...
Coagulation Analyzer Market Size, Share, Trends, Growth, Production, Consumption, Revenue, Company Analysis and Forecast 2021-2030Read more...
Biological Implants Market Size, Share, Trends, Growth, Production, Consumption, Revenue, Company Analysis and Forecast 2021-2030Read more...
Automated Dispensing Machines Market Size, Share, Trends, Growth, Production, Consumption, Revenue, Company Analysis and Forecast 2021-2030Read more...
Neurodiagnostics Market Size, Share, Trends, Growth, Production, Consumption, Revenue, Company Analysis and Forecast 2021-2030Read more...